Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

• Published in: Human vaccines & immunotherapeutics Vol. 17; no. 7; pp. 1882 - 1896
• Main Authors: Xu, Yuexin, Miller, Chris P., Warren, Edus H., Tykodi, Scott S.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 03.07.2021; Taylor & Francis Group
• Subjects: cancer vaccine; Renal cell carcinoma; Review; t cell receptor; tumor antigen; tumor-infiltrating T cell; tumor antigen; tumor-infiltrating T cell; Renal cell carcinoma; cancer vaccine; t cell receptor
• ISSN: 2164-5515; 2164-554X; 2164-554X
• DOI: 10.1080/21645515.2020.1870846

In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8 + T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.